Rifaximin and Cardiac Function in Patients with Heart Failure with Preserved Ejection Fraction

Summary

Single-center, double-blind, randomized, controlled intervention study of the effect of correction of bacterial overgrowth syndrome in the small intestine (SIBO) on cardiac function in patients with heart failure with preserved ejection fraction (HFpEF) (SIBO-HFpEF). The aim of the study is to evaluate the efficacy and safety of rifaximin in patients with HFpEF and SIBO.

Timeline

Start

2024-09-02

Primary completion

2026-09-30

Completion

2027-09-30

Drugs

Indications